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Dear Dr Mandeep R. Mehra and Dr Patricia Uber, 
Please find attached our revised manuscript (no. JHLT-D-13-00499) entitled, HEART 
TRANSPLANTATION IN PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS 
WITH POLYANGIITIS (CHURG–STRAUSS SYNDROME), by M Groh, G Masciocco, E 
Kirchner, et al, that we are resubmitting for publication as an Original Research 
Communication in the Journal of Heart and Lung Transplantation. 
We sincerely thank the Editorial Board members for their support of our paper and Reviewer 
1 for his/her time and pertinent remarks. Our detailed responses to the latter and the 
corresponding changes made in the text are given below. In the highlighted revised text, the 
deletions are double-barred and additions are in red. 
The total word count after modification is now 2526, with 2 references deleted, for a total of 
49 references in the revised manuscript. 
We hope that these changes have helped clarify the issues raised by the Reviewer and that you 
will find the revised manuscript acceptable for publication in the Journal of Heart and Lung 
Transplantation.  
We thank you in advance for your consideration and look forward to hearing from you soon. 
 
Sincerely yours, 
 
Matthieu Groh, MD 
 
 
 
 
 
 
 
 
*Author Response comments
REVIEWER 1 
Thus, I would suggest, if possible, to try making the paper more concise, taking 
advantage of the supplementary material, and focusing on the main messages that this 
important report bear:  
We fully agree with the Reviewer’s approach. Therefore, in the Results (pages 8 and 9–10), 
we deleted the information in the text that merely collated details given in Tables 1 and 4. In 
the Discussion (pages 11–12), we deleted the text that would be evident for transplant 
physicians and shortened the paragraph on connective diseases to facilitate reading and not 
cloud our messages. 
 
I would put more emphasis on the finding that no myocardial relapse was demonstrated 
in the post-transplant EMBs, except for the only case in which autopsy was performed.  
As mentioned in the online case series (page 2, second paragraph, lines 2–5), eosinophils 
suggestive of EGPA relapse were found in one of patient 1’s post-transplant EMBs 
(concomitant with an atrial fibrillation episode). Thus, evidence suggests that at least 2 
patients had post-transplant myocardial EGPA relapse. 
 
Did the EGPA scores improve after transplant? At page 10 of the revised version, 
authors report the differences in VDI scores in survivors vs. non survivors, indirectly 
suggesting that those who died had more pronounced signs of disease relapse.  
The vasculitis damage index records organ damage and sequelae that have occurred since the 
onset of vasculitis. Thus, this score can only rise during the course of the disease. In this 
series, the patients with the highest VDI scores (i.e., patients 2, 5, 6 and 8), most presumably 
because they have had the longest disease courses, are all still alive.  
 
Finally, I still believe that the statement "EGPA patients with heart transplants could be 
considered at high risk for arrhythmias" an over interpretation. First, it must be 
considered that arrhythmic risk after transplant is related to rejection and/or to CAV. 
Often "sudden" death in patients with CAV or rejection is associated with pulseless 
electric activity, and with AV blocks, rather than VT/TV.  Then, pre-transplant VT/TV 
episodes in patients 1,2,6, and 7 (page 12) cannot be considered as risk factors for post- 
transplant VT/TV. Finally, in any cardiac death the final mechanism of death is related 
to an inadequate electric activity, and thus is "arrhythmic". But this does not support 
the concept of "increased arrhythmic death".  
We concur with the Reviewer’s opinion. Hence, statements suggesting that EGPA patients 
might be at higher risk of arrhythmia have been deleted from the Abstract (page 3, paragraph 
4, lines 5–6) and the Discussion (page 12, fourth paragraph, lines 5–9) sections. 
 
Just a final brief comment on case 3: the likelihood that a patient dying with abdominal 
pain few days after a steroid load is due to rejection is as high as the likelihood that a 
cobra entered the bed and bit her.  
We fully agree with this comment. The Online Supplemental Material document has been 
modified (page 4, first paragraph, lines 4–7). 
 
A minor final comment, I think that the term "engraftment" may be more 
appropriately substituted by "transplant".  
The manuscript has been modified (page 11, second paragraph, line 2) accordingly.  
 
Supplemental tables with rejection grades may be redundant for JHLT readership. 
As suggested, the tables with rejection grades have been deleted from the Online 
Supplemental Material and table 3’s legend has been modified accordingly. 
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ABSTRACT 
 
BACKGROUND: Heart involvement is the leading cause of death of patients with eosinophilic 
granulomatosis with polyangiitis (formerly Churg–Strauss syndrome) (EGPA) and is more frequent in 
antineutrophil cytoplasm antibody (ANCA)-negative patients. Post-transplant outcome has only been 
reported once.  
METHODS: We conducted a retrospective international multicenter study. Patients satisfying the 
American College of Rheumatology and/or revised Chapel Hill Consensus Conference Nomenclature 
criteria were identified by collaborating vasculitis and transplant specialists, and the help of the 
Churg–Strauss Syndrome Association. 
RESULTS: Nine ANCA
–
 patients who received transplants between October 1987 and December 
2009 were identified. The vasculitis and cardiomyopathy diagnoses were concomitant for 5 patients 
and separated by 12–288 months for the remaining 4. Despite ongoing immunosuppression, histologic 
examination of 7 (78%) patients’ explanted hearts showed histologic patterns suggestive of active 
vasculitis. The overall 5-year survival rate was low (57%) but rose to 80% when considering only the 
6 patients transplanted during the last decade. After survival lasting 3–60 months, 4 (44%) patients 
died sudden deaths.  
CONCLUSIONS: The search for EGPA-related cardiomyopathy is mandatory early during the 
course of this vasculitis. Indeed, prompt treatment with corticosteroids and cyclophosphamide may 
achieve recovery of cardiac function. Most patients in this series were undertreated. For patients with 
refractory EGPA, heart transplantation should be performed and carries a fair prognosis. No optimal 
immunosuppressive strategy has yet been identified. Patients require close monitoring for arrhythmia 
post-transplantation. 
 
KEYWORDS: 
Churg–Strauss syndrome; hypereosinophilic syndrome; asthma; myocarditis; cardiomyopathy; heart 
transplantation; immunosuppression; cardiac arrhythmias 
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ABBREVIATIONS: 
ANCA, antineutrophil cytoplasm antibodies; BVAS, Birmingham Vasculitis Activity Score; CAV, 
cardiac allograft vasculopathy; CMR, cell-mediated rejection; CMRI, cardiac magnetic resonance 
imaging; EGPA, eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome); EMB, 
endomyocardial biopsy; ENT, ear, nose and throat; FFS, Five-Factor Score; ISHLT, International 
Society of Heart and Lung Transplantation; OHT, orthotopic heart transplantation; VDI, Vasculitis 
Damage Index. 
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Churg–Strauss syndrome, recently renamed eosinophilic granulomatosis with polyangiitis 
(Churg–Strauss syndrome) (EGPA),1 is a rare systemic necrotizing vasculitis that affects small- and 
medium-sized arteries. Its prevalence is 7–13 cases/million inhabitants,2-4 with an annual incidence of 
0.5–6.8 new cases/million inhabitants.5 Although its incidence is higher among asthmatic patients,6,7 
EGPA remains poorly known by most physicians. Its hallmark symptoms combine asthma, 
hypereosinophilia, systemic signs of vasculitis (especially mononeuritis multiplex) and anti-neutrophil 
cytoplasm antibodies (ANCAs) in 30–40% of the patients.8-10  
Heart involvement occurs in approximately 8–20% of EGPA patients and is more frequent in 
ANCA
–
 patients.
8,9,11
 Because silent eosinophilic infiltration of the myocardium can remain 
subclinical, it is difficult to determine the true prevalence accurately. Moreover, the specificity of new 
imaging techniques (e.g. cardiac magnetic resonance imaging (CMRI) and fluoro-2-deoxyglucose 
positron-emission tomography) remains unclear.
12-15
 Various histologic patterns (e.g., necrotizing 
vasculitis, eosinophil-rich inflammatory infiltrates, extravascular granuloma, coronary arteritis, 
intracavitary thrombus and/or endomyocardial fibrosis) and clinical manifestations (e.g., pericarditis, 
myocarditis, restrictive or dilated cardiomyopathy and arrhythmias) have been reported as EGPA-
related cardiac disease.
12,16,17
 Heart involvement, along with gastrointestinal, central nervous system 
and renal involvements, carries a poor prognosis and is part of the prognostic 1996 Five-Factor Score 
(FFS)
18
 and the 2009 revisited FFS.
19
 Pertinently, it is the leading cause of EGPA-associated 
deaths.
8,11
 Because disease remission is not achieved for all patients
 
and relapses are frequent,
20 
the 
possibility of orthotopic heart transplantation (OHT) feasibility in patients with refractory EGPA 
arises.  
Although the International Society for Heart and Lung Transplantation (ISHLT) does not 
consider systemic diseases contraindications for OHT,
21
 an acute flare and/or a high risk of post-
transplant disease recurrence often disqualifies patients from the procedure. Thus, according to some 
authors, EGPA is a limitation for OHT.
22
 Herein, we describe the outcomes post-OHT of 9 patients 
with EGPA-related cardiomyopathy.  
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Methods 
 
Patients 
 
Patients satisfying the 1990 American College of Rheumatology criteria for EGPA
23
 and/or the 
revised 2012 Chapel Hill Consensus Conference Nomenclature for EGPA
1
 were identified by 
collaborating vasculitis and transplant specialists, with the help of the Churg–Strauss Syndrome 
Association. All living patients gave informed consent for data collection and analysis.  
 
Assessments 
 
Medical charts were retrieved and reviewed for demographic, clinical, biologic, radiologic and 
histologic findings at the time of EGPA and EGPA-related–cardiomyopathy diagnoses. 
Cardiomyopathy was diagnosed based on clinical findings in combination with electrocardiogram and 
transthoracic echocardiography, thereby corresponding to the FFS definition.
18
 Pre-transplantation 
endomyocardial biopsies (EMBs) and histologic examination of explanted hearts were also noted as 
normal or showing signs of EGPA (e.g., vasculitis, granuloma, eosinophilic infiltrates), or non-
specific histologic patterns (i.e., myocardial fibrosis or atheroma). Finally, post-transplant EMB were 
recorded as described above, in addition to the search for histologic evidence of cell (CMR)- and 
antibody-mediated rejections, in accordance with the different ISHLT guidelines in force at the 
time.
24-26
  
 
Disease activity, severity and damage 
 
Using the 2003 revised Birmingham Vasculitis Activity Score (BVAS),
27 
the revisited FFS
19
 and the 
Vasculitis Damage Index (VDI),
28 
the vasculitis specialist retrospectively assessed disease activity, 
severity and damage. Briefly, the BVAS is a clinical index of disease activity comprising 56 items 
concerning 9 separate organ systems, which are scored (maximum score of 63) only if they are 
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attributable to active systemic necrotizing vasculitis. The FFS is a prognostic score that consists of 5 
items (including heart involvement) significantly associated with poorer outcomes. When the FFS is 
≥ 1, cyclophosphamide (or rituximab) combined with steroids is strongly recommended for ANCA-
associated vasculitides induction therapy.
29
 The VDI is a tool for evaluating organ damage that has 
occurred since the onset of vasculitis.
28
   
 
Outcomes 
 
Outcomes included EGPA relapses, post-transplant functional and working statuses at the last 
consultation, post-transplant complications and deaths. EGPA relapse was defined as 1) the 
recurrence or worsening of a clinical EGPA manifestation, after remission lasting ≥ 3 months, 2) 
requiring the addition or change of immunosuppressive drug(s) and/or the reinstitution of prednisone 
at a dose > 20 mg/day or an increase of the prednisone dose more than twice the previous dose and 
> 30 mg/day.
30
 Increased eosinophil count without any other clinical EGPA manifestation and 
isolated asthma or sinusitis exacerbations (with or without concomitant eosinophil-count rise) 
necessitating therapeutic adjustments were not considered EGPA relapses but were analyzed 
separately.  
Post-transplant complications comprised acute allograft rejection (CMR or antibody-
mediated), cardiac allograft vasculopathy ((CAV), as defined by the ISHLT standardized 
nomenclature),
31
 graft failure, infection, malignancy, chronic kidney disease, hypertension, diabetes 
mellitus, dyslipidemia and/or intensive care unit admission.  
 
  
 
 8 
Results 
 
Patients  
 
Nine patients (4 women and 5 men), who underwent OHT for EGPA-related cardiomyopathy between 
October 1987 and December 2009 in 8 transplant centers in 6 different countries, were identified. 
Their case reports are available in the Online Supplemental Material. Parts of patient 7–9’s medical 
histories were previously published
32-34 but only patient 9’s post-transplant outcome has been 
reported.
22
  
Table 1 summarizes the patients’ characteristics at EGPA diagnosis, when their median age 
was 36 (range 22–62) years. All patients had asthma, lung infiltrates and ANCA– serology (ANCA 
serology was not available at the time of patient 9’s EGPA diagnosis and no frozen serum was 
available for future analysis). None had concomitant gastrointestinal, central nervous system, eye or 
renal involvements. All seven (78%) patients with ear, nose and throat (ENT) manifestations had 
sinusitis and/or polyposis. Six (67%) patients had arthralgias and 5 (56%) myalgias. Three (33%) 
patients had a lung nodule. Four (44%) patients had skin manifestations: 2 (22%) with subcutaneous 
nodules and 3 (33%) with purpura. Mean eosinophilia at diagnosis was 9.4 ± 4.9 eosinophils/ml. 
 
EGPA-related cardiomyopathy 
 
Table 2 summarizes the patients’ characteristics at diagnosis of heart involvement. EGPA and 
cardiomyopathy were diagnosed concomitantly for 5 (56%) patients. For the 4 (44%) remaining 
patients, the interval between the 2 diagnoses was 12–288 months. All patients presented with severe 
acute eosinophilic myocarditis respective median (range) troponin I and N-terminal prohormone of 
brain natriuretic peptide concentrations: 8.85 (0.012–19.6) μg/liter and 3841 (601–32,397) pg/ml, 
abnormal ECG and severely diminished left ventricular ejection fraction (mean 24 ± 6%) due to 
active EGPA (mean BVAS 35 ± 9). Seven (78%) patients had dilated cardiomyopathy but none had 
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ventricular hypertrophy. Intracavitary thromboses were detected in 3 (33%) patients with dilated 
cardiomyopathy. Two (22%) patients underwent CMRI, which was suggestive of active vasculitis in 
both cases (Figure 1). Six (67%) patients had coronary angiograms but only patient 2’s was abnormal, 
revealing 40% stenosis of the anterior interventricular artery. BVAS at diagnosis of heart involvement 
ranged from 26 to 50 (mean 35 ± 9). The revised FFS equaled 1 point for 7 (78%) patients, and 2 
points for patients 5 and 9, who had no ENT manifestations when cardiomyopathy was diagnosed.  
 
Heart transplantation 
 
The interval between EGPA-related–cardiomyopathy diagnosis and OHT was 2–15 (mean 9 ± 4.8) 
months. All heart transplants were ABO compatible and had negative cross matches.  
 
Histologic findings  
 
Table 3 summarizes histologic findings. Seven (78%) patients had an EMB before transplant. Five 
were abnormal (with an eosinophil-rich infiltrate being the leading pattern found), but only 2 had 
EGPA-specific histologic findings. Intriguingly, despite ongoing immunosuppression, 7 (78%) 
patients’ explanted hearts still showed evidence of EGPA (Figure 2); among them, 6 (67%) had signs 
of active vasculitis. Six (67%) patients had non-specific histologic patterns with myocardial fibrosis 
being the most common. 
 
Therapeutic regimens 
 
All patients took corticosteroids before transplantation but only 5 (56%) were prescribed additional 
immunosuppressants and only 3 (33%) received cyclophosphamide pulses. Seven (78%) patients 
required vasoactive support and/or levosimendan pre-transplantation. Five (56%) patients had an 
intra-aortic balloon pump or ventricular heart-assist device during the pre-graft period.  
Table 4 summarizes post-operative care of the OHT recipients, where the details of 
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cardioactive treatments are available for 8 of the 9 patients. Seven (78%) patients received induction 
therapy, with antithymoglobulins being given to 5. Cyclosporine was the preferred calcineurin 
inhibitor, prescribed to 8 (89%) patients, whereas tacrolimus first-line therapy was given to only 1 
(11%). Patient 5 was switched from cyclosporine to everolimus because of chronic kidney disease, 
and patient 6 from cyclosporine to tacrolimus after a grade-1B CMR. Azathioprine was the preferred 
first-line anti-purine, prescribed to 6 (67%) patients, while mycophenolate mofetil was started in 3 
(33%). Patients 1 and 2 were switched from azathioprine to mycophenolate mofetil to treat EGPA 
relapse and toxidermia, respectively. Patient 5 was switched from mycophenolate mofetil to 
azathioprine to counter gastrointestinal intolerance.  
 
Post-transplant outcomes 
 
Of the 9 patients in this series, 4 (44%) died, all suddenly, with post-transplant survival lasting 3–60 
(mean 32 ± 29) months (Table 4). Follow-up for the 5 (56%) survivors was 55–102 (mean 74 ± 23) 
months, at this writing. At the last medical visit, VDI range was 0–2 (mean 1 ± 1) for the non-
survivors and 0–9 (mean 4.6 ± 3.6) for the survivors. Three (33%) patients experienced EGPA 
relapses, with the transplant-to-first-relapse interval lasting 2–48 months. Three (33%) additional 
patients suffered post-graft asthma and/or sinusitis flares that required increased corticosteroid doses. 
 All patients experienced post-transplant complications. Infection and CMR were the most 
frequent, occurring in 6 (67%) patients each. The transplant-to-heart-rejection interval ranged from 1 
to 74 (mean 23 ± 28) months. No graft failure or malignancy was reported. Lastly, only 3 (38%) 
patients reported some activity limitations and none required assistance for daily life activities.  
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Discussion 
 
The clinical phenotypes of ANCA
+
 and ANCA
–
 EGPA patients differ.
8-10
 ANCA
+
 patients have a 
vasculitic phenotype, with more frequent glomerulonephritis, mononeuritis multiplex and relapses. 
Although ANCA
–
 patients have fewer relapses, they have poorer prognoses, presumably because they 
have more frequent cardiomyopathy.
8,11
 According to multivariate analysis, heart involvement is the 
strongest independent predictor of EGPA-attributable mortality.
8
 Notably, all patients in this series 
were ANCA
–
, which is consistent with previously published data on EGPA-related heart 
involvement.
8,9,12,15
 Despite the low number of patients considered herein, several other pertinent 
observations can be made. 
First, most patients were undertreated and transplanted while their EGPA was active. Indeed, 
only 3 patients received cyclophosphamide pulses before engraftment transplant and, despite ongoing 
immunosuppression, 6 patients’ explanted hearts showed histologic patterns of active vasculitis. 
Physicians should be aware that, because it is life-threatening, EGPA cardiac involvement must be 
identified early during the course of this vasculitis and that it requires immediate therapy with 
corticosteroids and cyclophosphamide pulses, which may achieve recovery of cardiac function.
35,36
 
Pertinently, both patients without histologic evidence of cardiac EGPA received early corticosteroid 
therapy and pulse cyclophosphamide, thereby highlighting that an aggressive immunosuppressive 
strategy might induce vasculitis remission pre-transplantation. In addition, it is highly likely that 
patient 2 and 6’s initial symptoms were already EGPA-related cardiac manifestations but, 
unfortunately, they were not immediately diagnosed as such. We recommend complementary cardiac 
investigations for EGPA patients (especially those ANCA
–
) not only to properly evaluate 
symptomatic patients but, above all, to detect cardiac involvement in asymptomatic patients. CMRI 
seems to be more sensitive than echocardiography for this assessment but its specificity remains 
unclear.
12-14
 In addition to diagnostic imaging, and as recommended by the European Society of 
Cardiology, American Heart Association and American College of Cardiology Foundation,
37
 EMB 
should be obtained from patients with unexplained heart failure associated with eosinophilia, ideally 
before starting immunosuppressants. 
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Second, OHT is feasible in patients with refractory EGPA and carries a fair prognosis. 
Although the overall 5-year post-transplant survival rate was low (57%), it rose to 80% when we 
considered only the 6 patients (i.e. patients 1, 2, 4, 5, 7 and 8) transplanted during the last decade. 
These data are in agreement with recent findings showing that post-transplant survival of patients with 
pre-transplant hypersensitivity myocarditis (which shares some common histologic patterns with 
EGPA)
38
 or lymphocytic myocarditis
39
 was the same (albeit with more frequent late CMRs) as that of 
patients transplanted for other causes.  
Unfortunately, data on OHT in patients with other systemic diseases are very scarce.
40-43
 So 
far, only 8 systemic lupus erythematosus patients who underwent OHT have been reported.
40
 Six had 
fair outcomes (follow-up lasting up to 4 years) but 2 with secondary anti-phospholipid syndrome died 
of thrombosis. Moreover, OHT in only 1 patient with rheumatoid and dilated cardiomyopathy has 
been published.
41
 Lastly, although lung transplantation has been described in several patients with 
systemic sclerosis,
42
 the first OHT in this setting was reported only recently.
43
 Generally speaking, for 
patients with systemic diseases, an individualized approach, considering cardiac disease severity, the 
likelihood of underlying disease relapse post-transplantation and the presence of other comorbidities, 
seems reasonable. Ideally, EGPA patients should undergo transplantation after corticosteroids and 
pulse cyclophosphamide induction has achieved vasculitis remission.  
Evidently, OHT in this setting should also follow the ISHLT guidelines for the management 
of heart transplant recipients.
44 
Among others, patients should be strictly monitored for cardiovascular 
risk factors, receive antimicrobial prophylaxis to reduce the risks of cytomegalovirus and protozoan 
infections, and take statins to prevent CAV.  
Third, although OHT is feasible in EGPA, some patients had poor outcomes and 4 died 
sudden deaths. Postmortem examination of patient 9’s transplanted heart showed severe CAV, CMR 
and EGPA relapse. Unfortunately, the 3 other patients were not autopsied. Thus, we can only 
speculate about the causes of their deaths but acute arrhythmia due to CAV, myocardial fibrosis, 
vasculitis relapse and/or graft rejections are plausible explanations. Furthermore, ventricular 
tachycardia and/or ventricular fibrillation episodes were recorded pre-engraftment in patients 1, 2, 6 
and 7, and recent findings suggest that patients with non-ischemic cardiomyopathy and ventricular 
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tachycardia have extensive myocardial scars, which can lead to arrhythmia.
45
 Thus, EGPA patients 
with heart transplants could be considered at high risk for arrhythmias. 
Fourth, the absence of an optimal immunosuppressive strategy might have had a negative 
impact on the patients’ outcomes. Although post-transplant induction therapy remains controversial, it 
could be beneficial for patients at high risk for acute rejection and/or renal dysfunction.
44
 Moreover, 
to date, information is insufficient to recommend anti-interleukin-2–receptor antibodies or 
antithymoglobulins.
46 
Maintenance therapy after OHT combines a calcineurin inhibitor with an anti-
purine or a proliferation-signal inhibitor. Recent findings suggest that tacrolimus is superior to 
microemulsion cyclosporine with regard to acute severe biopsy-proven rejection,
44
 hypertension, 
hyperlipidemia, viral infections and CAV.
45 
Unfortunately, information on tacrolimus use in EGPA is 
scarce.
46 
Notably, only patient 8 received first-line tacrolimus and has had no EGPA flares and is 
doing well 6 years post-OHT. Azathioprine was the preferred first-line anti-purine. However, recent 
observations showed that post-transplant use of azathioprine rather than mycophenolate mofetil or 
mycophenolic acid increased the risk of CAV, malignancy and/or death.
47
 Unlike other ANCA-
associated vasculitides,
48 
no data are available comparing azathioprine vs mycophenolate mofetil as 
EGPA maintenance therapy. Lastly, the ISHLT recommends corticosteroid withdrawal 3–6 months 
after transplant for low-risk patients,
49 
but that goal seems difficult to achieve in EGPA patients who 
often require persistent low-dose corticosteroids to control their asthma. Furthermore, standard post-
transplant immunosuppressive therapy was unable to control EGPA in some patients. Indeed, 6 
patients’ EGPA relapsed or they experienced asthma flares, requiring higher corticosteroid doses than 
those routinely used in heart-transplant recipients. Therefore, in this setting, we recommend using an 
aggressive immunosuppressive protocol to avoid graft rejection and disease progression. 
Nevertheless, immunosuppression should be tailored individually. 
Finally, taking into account the possibility of late rejection and/or EGPA relapse, indefinite 
surveillance with a yearly EMB is probably reasonable. However, individual considerations, the risk 
of the procedure and the reduced diagnostic yield of repeated EMBs might plead for a less invasive 
approach, perhaps 2 years after transplantation. The latter could comprise strict monitoring of 
inflammatory parameters and eosinophil activation, dosage of myocardial necrosis markers, non-
  
 
 14 
invasive approaches for the diagnosis of acute cardiac allograft rejection, donor-specific antibody 
monitoring, and cardiac function evaluation with repeated echocardiography and/or CMRI (which can 
also be useful to guide the need for EMB).  
While this study brings new findings to light, its limitations include the retrospective design 
and the small number of EGPA patients worldwide who have received heart transplants. OHT in 
EGPA is a very rare situation and more data are needed to improve patient care. 
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Figure legends   
 
Figure 1. Cardiac magnetic resonance imaging of patient 2. (A) Short-axis view of 3-dimensional 
delayed-enhancement T1-weighted gradient-echo inversion-recovery magnetic resonance image 
(repetition time: 1.4 ms; echo time: 600 ms; inversion time: 250 ms) showing septal myocardial 
delayed enhancement (arrow). (B) Short-axis view of 2-dimensional inversion recovery, black blood 
fast spin-echo image (repetition time: 700 ms; echo time: 47 ms; inversion time: 170 ms) showing 
septal myocardial T2-weighted hyperintensity (arrow) consistent with edema.  
 
Figure 2.  Histopathologic examination of patient 1’s explanted heart. (A) Cardiectomy: high-grade 
bi-ventricular dilation with myocardial fibrosis and focal areas of macroscopic interstitial fibrosis 
(arrows) unrelated to coronary territory. (B) Interstitial focus of fibrinoid necrosis (A) encircled by 
epithelioid histiocytes, a giant cell (B), eosinophils (C) and lymphocytes (§). Hematoxylin-and-eosin 
stain, × 200.  
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ABSTRACT 
 
BACKGROUND: Heart involvement is the leading cause of death of patients with eosinophilic 
granulomatosis with polyangiitis (formerly Churg–Strauss syndrome) (EGPA) and is more frequent in 
antineutrophil cytoplasm antibody (ANCA)-negative patients. Post-transplant outcome has only been 
reported once.  
METHODS: We conducted a retrospective international multicenter study. Patients satisfying the 
American College of Rheumatology and/or revised Chapel Hill Consensus Conference Nomenclature 
criteria were identified by collaborating vasculitis and transplant specialists, and the help of the 
Churg–Strauss Syndrome Association. 
RESULTS: Nine ANCA
–
 patients who received transplants between October 1987 and December 
2009 were identified. The vasculitis and cardiomyopathy diagnoses were concomitant for 5 patients 
and separated by 12–288 months for the remaining 4. Despite ongoing immunosuppression, histologic 
examination of 7 (78%) patients’ explanted hearts showed histologic patterns suggestive of active 
vasculitis. The overall 5-year survival rate was low (57%) but rose to 80% when considering only the 
6 patients transplanted during the last decade. After survival lasting 3–60 months, 4 (44%) patients 
died sudden deaths.  
CONCLUSIONS: The search for EGPA-related cardiomyopathy is mandatory early during the 
course of this vasculitis. Indeed, prompt treatment with corticosteroids and cyclophosphamide may 
achieve recovery of cardiac function. Most patients in this series were undertreated. For patients with 
refractory EGPA, heart transplantation should be performed and carries a fair prognosis. No optimal 
immunosuppressive strategy has yet been identified.  
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KEYWORDS: 
Churg–Strauss syndrome; hypereosinophilic syndrome; asthma; myocarditis; cardiomyopathy; heart 
transplantation; immunosuppression; cardiac arrhythmias 
 
ABBREVIATIONS: 
ANCA, antineutrophil cytoplasm antibodies; BVAS, Birmingham Vasculitis Activity Score; CAV, 
cardiac allograft vasculopathy; CMR, cell-mediated rejection; CMRI, cardiac magnetic resonance 
imaging; EGPA, eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome); EMB, 
endomyocardial biopsy; ENT, ear, nose and throat; FFS, Five-Factor Score; ISHLT, International 
Society of Heart and Lung Transplantation; OHT, orthotopic heart transplantation; VDI, Vasculitis 
Damage Index. 
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Churg–Strauss syndrome, recently renamed eosinophilic granulomatosis with polyangiitis 
(Churg–Strauss syndrome) (EGPA),1 is a rare systemic necrotizing vasculitis that affects small- and 
medium-sized arteries. Its prevalence is 7–13 cases/million inhabitants,2-4 with an annual incidence of 
0.5–6.8 new cases/million inhabitants.5 Although its incidence is higher among asthmatic patients,6,7 
EGPA remains poorly known by most physicians. Its hallmark symptoms combine asthma, 
hypereosinophilia, systemic signs of vasculitis (especially mononeuritis multiplex) and anti-neutrophil 
cytoplasm antibodies (ANCAs) in 30–40% of the patients.8-10  
Heart involvement occurs in approximately 8–20% of EGPA patients and is more frequent in 
ANCA
–
 patients.
8,9,11
 Because silent eosinophilic infiltration of the myocardium can remain 
subclinical, it is difficult to determine the true prevalence accurately. Moreover, the specificity of new 
imaging techniques (e.g. cardiac magnetic resonance imaging (CMRI) and fluoro-2-deoxyglucose 
positron-emission tomography) remains unclear.
12-15
 Various histologic patterns (e.g., necrotizing 
vasculitis, eosinophil-rich inflammatory infiltrates, extravascular granuloma, coronary arteritis, 
intracavitary thrombus and/or endomyocardial fibrosis) and clinical manifestations (e.g., pericarditis, 
myocarditis, restrictive or dilated cardiomyopathy and arrhythmias) have been reported as EGPA-
related cardiac disease.
12,16,17
 Heart involvement, along with gastrointestinal, central nervous system 
and renal involvements, carries a poor prognosis and is part of the prognostic 1996 Five-Factor Score 
(FFS)
18
 and the 2009 revisited FFS.
19
 Pertinently, it is the leading cause of EGPA-associated 
deaths.
8,11
 Because disease remission is not achieved for all patients
 
and relapses are frequent,
20 
the 
possibility of orthotopic heart transplantation (OHT) feasibility in patients with refractory EGPA 
arises.  
Although the International Society for Heart and Lung Transplantation (ISHLT) does not 
consider systemic diseases contraindications for OHT,
21
 an acute flare and/or a high risk of post-
transplant disease recurrence often disqualifies patients from the procedure. Thus, according to some 
authors, EGPA is a limitation for OHT.
22
 Herein, we describe the outcomes post-OHT of 9 patients 
with EGPA-related cardiomyopathy.  
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Methods 
 
Patients 
 
Patients satisfying the 1990 American College of Rheumatology criteria for EGPA
23
 and/or the 
revised 2012 Chapel Hill Consensus Conference Nomenclature for EGPA
1
 were identified by 
collaborating vasculitis and transplant specialists, with the help of the Churg–Strauss Syndrome 
Association. All living patients gave informed consent for data collection and analysis.  
 
Assessments 
 
Medical charts were retrieved and reviewed for demographic, clinical, biologic, radiologic and 
histologic findings at the time of EGPA and EGPA-related–cardiomyopathy diagnoses. 
Cardiomyopathy was diagnosed based on clinical findings in combination with electrocardiogram and 
transthoracic echocardiography, thereby corresponding to the FFS definition.
18
 Pre-transplantation 
endomyocardial biopsies (EMBs) and histologic examination of explanted hearts were also noted as 
normal or showing signs of EGPA (e.g., vasculitis, granuloma, eosinophilic infiltrates), or non-
specific histologic patterns (i.e., myocardial fibrosis or atheroma). Finally, post-transplant EMB were 
recorded as described above, in addition to the search for histologic evidence of cell (CMR)- and 
antibody-mediated rejections, in accordance with the different ISHLT guidelines in force at the 
time.
24-26
  
 
Disease activity, severity and damage 
 
Using the 2003 revised Birmingham Vasculitis Activity Score (BVAS),
27 
the revisited FFS
19
 and the 
Vasculitis Damage Index (VDI),
28 
the vasculitis specialist retrospectively assessed disease activity, 
severity and damage. Briefly, the BVAS is a clinical index of disease activity comprising 56 items 
concerning 9 separate organ systems, which are scored (maximum score of 63) only if they are 
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attributable to active systemic necrotizing vasculitis. The FFS is a prognostic score that consists of 5 
items (including heart involvement) significantly associated with poorer outcomes. When the FFS is 
≥ 1, cyclophosphamide (or rituximab) combined with steroids is strongly recommended for ANCA-
associated vasculitides induction therapy.
29
 The VDI is a tool for evaluating organ damage that has 
occurred since the onset of vasculitis.
28
   
 
Outcomes 
 
Outcomes included EGPA relapses, post-transplant functional and working statuses at the last 
consultation, post-transplant complications and deaths. EGPA relapse was defined as 1) the 
recurrence or worsening of a clinical EGPA manifestation, after remission lasting ≥ 3 months, 2) 
requiring the addition or change of immunosuppressive drug(s) and/or the reinstitution of prednisone 
at a dose > 20 mg/day or an increase of the prednisone dose more than twice the previous dose and 
> 30 mg/day.
30
 Increased eosinophil count without any other clinical EGPA manifestation and 
isolated asthma or sinusitis exacerbations (with or without concomitant eosinophil-count rise) 
necessitating therapeutic adjustments were not considered EGPA relapses but were analyzed 
separately.  
Post-transplant complications comprised acute allograft rejection (CMR or antibody-
mediated), cardiac allograft vasculopathy ((CAV), as defined by the ISHLT standardized 
nomenclature),
31
 graft failure, infection, malignancy, chronic kidney disease, hypertension, diabetes 
mellitus, dyslipidemia and/or intensive care unit admission.  
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Results 
 
Patients  
 
Nine patients (4 women and 5 men), who underwent OHT for EGPA-related cardiomyopathy between 
October 1987 and December 2009 in 8 transplant centers in 6 different countries, were identified. 
Their case reports are available in the Online Supplemental Material. Parts of patient 7–9’s medical 
histories were previously published
32-34 but only patient 9’s post-transplant outcome has been 
reported.
22
  
Table 1 summarizes the patients’ characteristics at EGPA diagnosis, when their median age 
was 36 (range 22–62) years. All patients had asthma, lung infiltrates and ANCA– serology (ANCA 
serology was not available at the time of patient 9’s EGPA diagnosis and no frozen serum was 
available for future analysis). 
 
EGPA-related cardiomyopathy 
 
Table 2 summarizes the patients’ characteristics at diagnosis of heart involvement. EGPA and 
cardiomyopathy were diagnosed concomitantly for 5 (56%) patients. For the 4 (44%) remaining 
patients, the interval between the 2 diagnoses was 12–288 months. All patients presented with severe 
acute eosinophilic myocarditis respective median (range) troponin I and N-terminal prohormone of 
brain natriuretic peptide concentrations: 8.85 (0.012–19.6) μg/liter and 3841 (601–32,397) pg/ml, 
abnormal ECG and severely diminished left ventricular ejection fraction (mean 24 ± 6%) due to 
active EGPA (mean BVAS 35 ± 9). Seven (78%) patients had dilated cardiomyopathy but none had 
ventricular hypertrophy. Intracavitary thromboses were detected in 3 (33%) patients with dilated 
cardiomyopathy. Two (22%) patients underwent CMRI, which was suggestive of active vasculitis in 
both cases (Figure 1). Six (67%) patients had coronary angiograms but only patient 2’s was abnormal, 
revealing 40% stenosis of the anterior interventricular artery. BVAS at diagnosis of heart involvement 
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ranged from 26 to 50 (mean 35 ± 9). The revised FFS equaled 1 point for 7 (78%) patients, and 2 
points for patients 5 and 9, who had no ENT manifestations when cardiomyopathy was diagnosed.  
 
Heart transplantation 
 
The interval between EGPA-related–cardiomyopathy diagnosis and OHT was 2–15 (mean 9 ± 4.8) 
months. All heart transplants were ABO compatible and had negative cross matches.  
 
Histologic findings  
 
Table 3 summarizes histologic findings. Seven (78%) patients had an EMB before transplant. Five 
were abnormal (with an eosinophil-rich infiltrate being the leading pattern found), but only 2 had 
EGPA-specific histologic findings. Intriguingly, despite ongoing immunosuppression, 7 (78%) 
patients’ explanted hearts still showed evidence of EGPA (Figure 2); among them, 6 (67%) had signs 
of active vasculitis. Six (67%) patients had non-specific histologic patterns with myocardial fibrosis 
being the most common. 
 
Therapeutic regimens 
 
All patients took corticosteroids before transplantation but only 5 (56%) were prescribed additional 
immunosuppressants and only 3 (33%) received cyclophosphamide pulses. Seven (78%) patients 
required vasoactive support and/or levosimendan pre-transplantation. Five (56%) patients had an 
intra-aortic balloon pump or ventricular heart-assist device during the pre-graft period.  
Table 4 summarizes post-operative care of the OHT recipients, where the details of 
cardioactive treatments are available for 8 of the 9 patients.  
 
Post-transplant outcomes 
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Of the 9 patients in this series, 4 (44%) died, all suddenly, with post-transplant survival lasting 3–60 
(mean 32 ± 29) months (Table 4). Follow-up for the 5 (56%) survivors was 55–102 (mean 74 ± 23) 
months, at this writing. At the last medical visit, VDI range was 0–2 (mean 1 ± 1) for the non-
survivors and 0–9 (mean 4.6 ± 3.6) for the survivors. Three (33%) patients experienced EGPA 
relapses, with the transplant-to-first-relapse interval lasting 2–48 months. Three (33%) additional 
patients suffered post-graft asthma and/or sinusitis flares that required increased corticosteroid doses. 
 All patients experienced post-transplant complications. Infection and CMR were the most 
frequent, occurring in 6 (67%) patients each. The transplant-to-heart-rejection interval ranged from 1 
to 74 (mean 23 ± 28) months. No graft failure or malignancy was reported. Lastly, only 3 (38%) 
patients reported some activity limitations and none required assistance for daily life activities.  
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Discussion 
 
The clinical phenotypes of ANCA
+
 and ANCA
–
 EGPA patients differ.
8-10
 ANCA
+
 patients have a 
vasculitic phenotype, with more frequent glomerulonephritis, mononeuritis multiplex and relapses. 
Although ANCA
–
 patients have fewer relapses, they have poorer prognoses, presumably because they 
have more frequent cardiomyopathy.
8,11
 According to multivariate analysis, heart involvement is the 
strongest independent predictor of EGPA-attributable mortality.
8
 Notably, all patients in this series 
were ANCA
–
, which is consistent with previously published data on EGPA-related heart 
involvement.
8,9,12,15
 Despite the low number of patients considered herein, several other pertinent 
observations can be made. 
First, most patients were undertreated and transplanted while their EGPA was active. Indeed, 
only 3 patients received cyclophosphamide pulses before transplant and, despite ongoing 
immunosuppression, 6 patients’ explanted hearts showed histologic patterns of active vasculitis. 
Physicians should be aware that, because it is life-threatening, EGPA cardiac involvement must be 
identified early during the course of this vasculitis and that it requires immediate therapy with 
corticosteroids and cyclophosphamide pulses, which may achieve recovery of cardiac function.
35,36
 
Pertinently, both patients without histologic evidence of cardiac EGPA received early corticosteroid 
therapy and pulse cyclophosphamide, thereby highlighting that an aggressive immunosuppressive 
strategy might induce vasculitis remission pre-transplantation. In addition, it is highly likely that 
patient 2 and 6’s initial symptoms were already EGPA-related cardiac manifestations but, 
unfortunately, they were not immediately diagnosed as such. We recommend complementary cardiac 
investigations for EGPA patients (especially those ANCA
–
) not only to properly evaluate 
symptomatic patients but, above all, to detect cardiac involvement in asymptomatic patients. CMRI 
seems to be more sensitive than echocardiography for this assessment but its specificity remains 
unclear.
12-14
 In addition to diagnostic imaging, and as recommended by the European Society of 
Cardiology, American Heart Association and American College of Cardiology Foundation,
37
 EMB 
should be obtained from patients with unexplained heart failure associated with eosinophilia, ideally 
before starting immunosuppressants. 
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Second, OHT is feasible in patients with refractory EGPA and carries a fair prognosis. 
Although the overall 5-year post-transplant survival rate was low (57%), it rose to 80% when we 
considered only the 6 patients (i.e. patients 1, 2, 4, 5, 7 and 8) transplanted during the last decade. 
These data are in agreement with recent findings showing that post-transplant survival of patients with 
pre-transplant hypersensitivity myocarditis (which shares some common histologic patterns with 
EGPA)
38
 or lymphocytic myocarditis
39
 was the same (albeit with more frequent late CMRs) as that of 
patients transplanted for other causes.  
Unfortunately, data on OHT in patients with other systemic diseases are very scarce.
40-43
 
Generally speaking, for patients with systemic diseases, an individualized approach, considering 
cardiac disease severity, the likelihood of underlying disease relapse post-transplantation and the 
presence of other comorbidities, seems reasonable. Ideally, EGPA patients should undergo 
transplantation after corticosteroids and pulse cyclophosphamide induction has achieved vasculitis 
remission.  
Third, although OHT is feasible in EGPA, some patients had poor outcomes and 4 died 
sudden deaths. Postmortem examination of patient 9’s transplanted heart showed severe CAV, CMR 
and EGPA relapse. Unfortunately, the 3 other patients were not autopsied. Thus, we can only 
speculate about the causes of their deaths but acute arrhythmia due to CAV, myocardial fibrosis, 
vasculitis relapse and/or graft rejections are plausible explanations.  
Fourth, the absence of an optimal immunosuppressive strategy might have had a negative 
impact on the patients’ outcomes. Maintenance therapy after OHT combines a calcineurin inhibitor 
with an anti-purine or a proliferation-signal inhibitor. Recent findings suggest that tacrolimus is 
superior to microemulsion cyclosporine with regard to acute severe biopsy-proven rejection,
44
 
hypertension, hyperlipidemia, viral infections and CAV.
45 
Unfortunately, information on tacrolimus 
use in EGPA is scarce. Azathioprine was the preferred first-line anti-purine. However, recent 
observations showed that post-transplant use of azathioprine rather than mycophenolate mofetil or 
mycophenolic acid increased the risk of CAV, malignancy and/or death.
47
 Unlike other ANCA-
associated vasculitides,
48 
no data are available comparing azathioprine vs mycophenolate mofetil as 
EGPA maintenance therapy. Lastly, the ISHLT recommends corticosteroid withdrawal 3–6 months 
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after transplant for low-risk patients,
49 
but that goal seems difficult to achieve in EGPA patients who 
often require persistent low-dose corticosteroids to control their asthma. Furthermore, standard post-
transplant immunosuppressive therapy was unable to control EGPA in some patients. Indeed, 6 
patients’ EGPA relapsed or they experienced asthma flares, requiring higher corticosteroid doses than 
those routinely used in heart-transplant recipients. Therefore, in this setting, we recommend using an 
aggressive immunosuppressive protocol to avoid graft rejection and disease progression. 
Nevertheless, immunosuppression should be tailored individually. 
Finally, taking into account the possibility of late rejection and/or EGPA relapse, indefinite 
surveillance with a yearly EMB is probably reasonable. However, individual considerations, the risk 
of the procedure and the reduced diagnostic yield of repeated EMBs might plead for a less invasive 
approach, perhaps 2 years after transplantation. The latter could comprise strict monitoring of 
inflammatory parameters and eosinophil activation, dosage of myocardial necrosis markers, non-
invasive approaches for the diagnosis of acute cardiac allograft rejection, donor-specific antibody 
monitoring, and cardiac function evaluation with repeated echocardiography and/or CMRI (which can 
also be useful to guide the need for EMB).  
While this study brings new findings to light, its limitations include the retrospective design 
and the small number of EGPA patients worldwide who have received heart transplants. OHT in 
EGPA is a very rare situation and more data are needed to improve patient care. 
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Figure legends   
 
Figure 1. Cardiac magnetic resonance imaging of patient 2. (A) Short-axis view of 3-dimensional 
delayed-enhancement T1-weighted gradient-echo inversion-recovery magnetic resonance image 
(repetition time: 1.4 ms; echo time: 600 ms; inversion time: 250 ms) showing septal myocardial 
delayed enhancement (arrow). (B) Short-axis view of 2-dimensional inversion recovery, black blood 
fast spin-echo image (repetition time: 700 ms; echo time: 47 ms; inversion time: 170 ms) showing 
septal myocardial T2-weighted hyperintensity (arrow) consistent with edema.  
 
Figure 2.  Histopathologic examination of patient 1’s explanted heart. (A) Cardiectomy: high-grade 
bi-ventricular dilation with myocardial fibrosis and focal areas of macroscopic interstitial fibrosis 
(arrows) unrelated to coronary territory. (B) Interstitial focus of fibrinoid necrosis (A) encircled by 
epithelioid histiocytes, a giant cell (B), eosinophils (C) and lymphocytes (§). Hematoxylin-and-eosin 
stain, × 200.  
 1 
ABBREVIATIONS 
AMR, antibody-mediated rejection; ANCA, antineutrophil cytoplasm antibodies; CAV, cardiac 
allograft vasculopathy; CHF, congestive heart failure; CMRI, cardiac magnetic resonance imaging; 
CMR, cell-mediated rejection; CMV, cytomegalovirus; CT, computed tomography; EGPA, 
eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome); EMB, endomyocardial 
biopsy; ENT = ear, nose and throat; IABP, intra-aortic balloon pump; HLA, human lymphocyte 
antigen; ICU, intensive care unit; LVEF, left ventricular ejection fraction; MF, myocardial fibrosis; 
OHT, orthotopic heart transplantation. 
 
CASE REPORTS 
 
Case 1  
 
A woman born in 1955 was diagnosed with eosinophilic granulomatosis with polyangiitis (Churg–
Strauss syndrome) (EGPA) in 1985 based on asthma, differential white-blood-cell–count eosinophilia, 
non-fixed pulmonary infiltrates, chronic paranasal sinus pain, skin biopsy showing perivascular 
inflammation with dense eosinophilic infiltrate and giant-cell granuloma in a context of arthralgias and 
pericarditis. Antineutrophil cytoplasm antibody (ANCA) serology was negative. Various treatments 
including azathioprine, methotrexate, cyclosporine and mycophenolate mofetil were administered until 
2009. During those years, she had many relapses, and successively developed polyneuritis, retro-
tympanic granuloma and eosinophilic gastroenteritis, while control of her asthma required continuous 
corticosteroids.  
In 2009, mitral regurgitation and severe dilated cardiomyopathy with left ventricular ejection 
fraction (LVEF) estimated at 33% were diagnosed. Coronary angiogram was normal. Despite 
cardioactive treatment, several episodes of acute congestive heart failure (CHF) and an episode of 
ventricular tachycardia treated with amiodarone occurred. Orthotopic heart transplantation (OHT) was 
performed in December 2009 in Niguarda Ca’ Granda Hospital in Milan, Italy. Histopathologic 
examination of the explanted heart found extensive myocardial fibrosis (MF), fibrinoid necrosis and 
ONLINE SUPPLEMENTARY MATERIAL WITH CHANGES HIGHLIGHTED
 2 
an eosinophil-rich infiltrate (Figure 2). Outcome was favorable with immunosuppressive therapy 
(cyclosporine 175 mg bid, and azathioprine 75 mg/day enabling prednisone tapering), cardioactive 
therapy (atenolol 25 mg/day, ramipril 2.5 mg/day, aspirin 100 mg/day, and simavastatin 20 mg/day) 
and anti-cytomegalovirus (CMV) prophylaxis (valganciclovir 450 mg/day). 
 In February 2010, the patient developed atrial fibrillation, which was successfully treated with 
electrical cardioversion. Endomyocardial biopsy (EMB) showed a mixed acute cell (CMR)- and 
antibody-mediated rejections (AMR) (graded 1R and pAMR2, respectively; see Tables S1 and S2for 
explanations of acute CMR and AMR gradings) and eosinophilic granulocytes suggestive EGPA 
recurrence. Her health improved with intravenous immunoglobulins (25 g/day for 5 days) and pulse 
corticosteroids. Methotrexate (15 mg/week) was started and azathioprine was replaced by 
mycophenolate mofetil (550 mg bid). Since then, all EMBs have been normal.  
In July 2011, despite the absence of clinical or biologic signs of EGPA activity, the patient 
died suddenly. No autopsy was performed. 
 
Case 2  
 
In July 2007, a 52-year-old man, with a 3-year history of asthma and a CHF episode with normal 
coronary angiogram 3 years earlier, was diagnosed with EGPA: late asthma, non-fixed pulmonary 
infiltrates, sinusitis, eosinophilia (13.9 cells/ml), myocarditis, arthralgias and myalgias. ANCA 
serology was negative. Because of EGPA-related heart involvement, corticosteroids and 6 
cyclophosphamide pulses were prescribed.   
Two months later, he was admitted to the intensive care unit (ICU) with cardiac arrest. ECG 
showed asystole caused by severe hyperkalemia and renal failure resulting from decompensated 
corticosteroid-induced diabetes and angiotensin-converting-enzyme–inhibitor treatment. He recovered 
normal electric activity after cardiopulmonary resuscitation and adrenaline. His condition improved 
with insulin therapy and volume resuscitation. Azathioprine (150 mg/day) maintenance therapy was 
started but soon replaced by mycophenolate mofetil (1 g bid) due to toxidermia. 
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In January 2008, when a -blocker was introduced, his condition worsened. Cardiac magnetic 
resonance imaging (CMRI) (Figure 2) revealed severe dilated cardiomyopathy, mitral regurgitation, 
subepicardial delayed contrast enhancement in the septum and anterior wall, and T2-weighted 
hyperintensity in the same myocardial territory, consistent with edema. These findings were 
suggestive of active EGPA-related cardiomyopathy. He underwent OHT in March 2008 at Pitié–
Salpêtrière Hospital, Paris, France. Despite numerous post-operative complications (septic 
mediastinitis, septic shock due to Enterobacter aerogenes ventilator-associated pneumonia, acute 
CMV infection, severe polyneuromyopathy and chronic diarrhea due to Enterocytozoon bieneusi), he 
achieved full neurologic and functional recovery. However, he developed chronic kidney disease 
(glomerular filtration rate 40 ml/minute in 2012) as sequelae. Thirteen months post-OHT, EMB 
showed an acute grade-1R CMR (asymptomatic thus not requiring corticosteroids). Twenty-one 
months later, an asthma exacerbation required increasing the prednisone dose. 
Four years post-OHT, under a regimen of prednisone (10 mg/day), cyclosporine and 
mycophenolate mofetil, he has experienced no EGPA relapse or other graft rejection in routine EMBs.  
  
Case 3 
 
In 1999, a 36-year-old woman developed late-onset asthma followed, in June 2000, by severe CHF, 
intracavitary thrombosis, bilateral transudative pleural effusions, skin purpura, sinusitis and 
eosinophilia (1.9 cells/ml). EGPA was diagnosed in September 2000. ANCA serology was negative. 
Segmental pulmonary embolism and a right apical nodule were fortuitously diagnosed on her 
computed-tomography (CT) scan. EMB was uninformative. Despite corticosteroids, anticoagulant and 
cyclophosphamide pulses, she was transferred to the ICU under dobutamine, high-dose furosemide 
and interferon-α (3 MIU 3 times a week) added to her regimen. Echocardiography after dobutamine 
withdrawal estimated her LVEF at 15%. OHT was performed in October 2000 at Pitié–Salpêtrière 
Hospital.  
 Under immunosuppressants (tapering doses of prednisone, azathioprine 50 mg bid, 
cyclosporine 550 mg/day), her weekly EMB showed no sign of acute allograft rejection. In early 
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February 2001, she developed acute sinusitis and prednisone was increased to 60 mg/day by an ENT 
specialist. On 12 February 2001, she succumbed to sudden death, complaining of intense abdominal 
pain. Because no autopsy was performed, we can only speculate on the cause of her death. First, 
gastrointestinal perforation and subsequent fulminant peritonitis is a plausible explanation. Second, 
since no human leukocyte antigen (HLA) class-II gene typing was performed and there were 4 donor–
recipient HLA class-I mismatches, she was also at high immunologic risk. Thus, acute arrhythmia due 
to graft rejection is another plausible explanation. Lastly, even though she had received 
cyclophosphamide pulses prior to OHT and she was currently taking high corticosteroid doses, an 
EGPA relapse cannot be formally excluded. Second, even though she had received cyclophosphamide 
pulses prior to OHT and was currently taking high corticosteroid doses, an EGPA relapse cannot be 
formally excluded. Lastly, graft rejection seems highly unlikely in this setting. 
 
Case 4  
 
In February 2003, a 35-year-old woman with a 15-year history of adult-onset asthma developed 
fulminant CHF secondary to myocarditis, requiring an intra-aortic balloon pump support (IABP). 
Initial laboratory analyses revealed marked eosinophilia (9.6 cells/ml). Her chest X-ray showed diffuse 
perihilar infiltrates suggestive of pulmonary edema and pleural effusions. A week later, a thoracic 
computed-tomography (CT) scan revealed a left infrahilar nodule. Echocardiography estimated LVEF 
at 25%. Bronchoscopy was uninformative. The patient initially received medical support and 
hydrocortisone. Work-up for an infectious or atopic etiology was negative. Transbronchial biopsy of 
the lung lesion revealed a fibrinopurulent exudate with Charcot–Laden crystals consistent with 
degenerating eosinophils.  Prednisone (70 mg/day) was prescribed and she was discharged. 
Thereafter, she was readmitted for a fainting episode attributed to hypotension and referred to 
another center where EGPA was diagnosed in late June 2003. Azathioprine (50 mg tid) was started, 
and corticosteroids were tapered and then stopped by November 2003, when a control thoracic CT 
scan showed resolution of the lung mass. In January 2004, an upper respiratory infection was treated 
with antibiotics and prednisone (30 mg/day). In March 2004, despite azathioprine, echocardiography 
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found persistently low LVEF (20%) and a metabolic stress-test measured peak oxygen consumption at 
15.8 ml/kg/minute (50% of the predicted value for her age). OHT was performed 2 May 2004 at the 
Cleveland Clinic, Cleveland, OH, USA. On 10 May, she received corticosteroid pulses for grade-3R 
CMR. 
Six months post-OHT, the patient developed shingles and another upper respiratory infection. 
Prednisone was withdrawn but restarted in August 2005, when she was taking cyclosporine (100 mg 
qid) and mycophenolate mofetil (125 mg qid) because of recurrent eosinophilia and asthma 
exacerbation. Long-term post-OHT medications include cyclosporine (100 mg bid), mycophenolate 
mofetil (1 g bid), prednisone (4 mg qid), lisinopril (5 mg bid), aciclovir (800 mg bid) and 
bronchodilatators as needed. Eight years post-OHT, no major EGPA relapse has occurred and no graft 
rejection has been seen on routine EMBs. 
 
Case 5 
 
In 2004, a 50-year-old patient, with a history of several bronchitis episodes during winters, systemic 
hypertension and dyslipidemia was diagnosed with EGPA: late-onset asthma, arthralgias, myalgias, 
skin purpura and subcutaneous nodules, mononeuritis multiplex and blood eosinophilia (9.79 cells/ml). 
ANCA serology was negative. Corticosteroids were started (initially 1 mg/kg/day for 3 weeks then 
doses were tapered). 
 Eighteen months later, in December 2005, while the patient’s symptoms regressed under 
corticosteroids, he was admitted to the ICU for CHF, chest pain and high troponin I levels (> 8 pg/ml). 
An 18-lead ECG showed no ST-segment abnormality but a grade-1 atrioventricular block. 
Echocardiography estimated LVEF at 18%, global hypokinesia, dilated left heart chambers, moderate 
mitral insufficiency and pericardial effusion. Coronary angiogram was normal. Histologic examination 
of an EMB revealed fibrinoid necrosis, an eosinophil-rich inflammatory infiltrate, extravascular 
granulomas and MF, thereby confirming the diagnosis of EGPA-related cardiomyopathy. Despite 
intensive therapy and positive inotropic support, his condition worsened. Emergency OHT was 
performed in March 2006 in the Sanatorio de la Trinidad Mitre Hospital, Buenos Aires, Argentina. 
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The patient experienced several post-OHT complications. First, immunosuppressant side 
effects necessitated switching mycophenolate mofetil to azathioprine because of gastrointestinal 
disorders and cyclosporine to everolimus in early 2012 to counter moderate kidney failure, then 6 
years post-OHT he developed corticosteroid-associated aseptic necrosis of the hip requiring 
arthroplasty. Second, 2 years post-OHT he developed disseminated miliary tuberculosis (involving 
lung, peritoneum and skin) that was treated with a 12-months of anti-tuberculosis drugs (including 2 
months of quadritherapy); 2 years after the end of treatment, he suffered a skin relapse and is currently 
taking isoniazid and rifampicin. Third, EGPA relapsed (skin purpura) 48 months post-OHT requiring 
prednisone intensification. Finally, he was recently diagnosed with severe grade-3 cardiac allograft 
vasculopathy (CAV) on a routine coronary angiogram. He is currently taking prednisone (40 mg/day), 
everolimus (1.5 mg/day) and azathioprine (150 mg/day). 
 
Case 6  
 
A 62-year-old man, with a history of late-onset asthma, anaphylactic shock after a bee sting, 
polypectomy for nasal polyposis, systemic hypertension and ventricular extrasystoles treated since 
2007 with carvedilol and flecainide, was admitted to the ICU in March 2008 with CHF and anterior 
ST-segment elevation. Transthoracic echocardiography estimated LVEF at 25% and visualized 
anterior hypokinesia, moderate mitral and tricuspid regurgitations, and an apical thrombus. The 
coronary angiogram was normal and chest CT angiography showed no evidence of pulmonary 
embolism. Blood analyses revealed hypereosinophilia (12.5 cells/ml). The patient’s condition finally 
improved with positive inotropic support and standard medical therapy. In June 2008, before 
discharge, an automatic cardioverter defibrillator was implanted because of frequent episodes of 
unsustained ventricular tachycardia.  
In August 2008, he was readmitted for CHF and malignant hypertension unresponsive to 
dopamine, nitroprusside and diuretics, and he was transferred to the ICU, where adrenaline, milrinone 
and IABP were started. Blood hypereosinophilia was confirmed. EMB contained an eosinophil-rich 
inflammatory infiltrate and EGPA was diagnosed. The patient was started on corticosteroids and 
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underwent “extremely urgent” OHT on 16 September 2008 in Niguarda Ca’ Granda Hospital in Milan, 
Italy.  
The post-operative period was marked by acute CMV pneumonia, extended-spectrum -
lactamase Enterobacter cloacae sepsis and serum Aspergillus galactomannan antigen became positive. 
He was successfully treated with ganciclovir, imipenem and voriconazole. In January 2009, EMB 
showed acute grade-1R CMR. Pulse corticosteroids were not administered but cyclosporine 
maintenance was switched to tacrolimus. 
Four years post-OHT, under prednisone (7.5 mg/day), tacrolimus (5 mg/day) and azathioprine 
(50 mg/day), EMBs scheduled biannually have shown no evidence of graft rejection. The patient is 
well but has mild functional limitations due to chronic renal dysfunction and osteoporosis.  
 
Case 7  
 
A 35-year-old woman was diagnosed with EGPA in 2003. Part of her medical history was previously 
reported.
1
 A few weeks postpartum, she developed fever, severe asthma, skin petechiae, polyarthralgia 
and CHF. Blood tests revealed 17.5 eosinophils/ml and a high troponin I level. ANCA serology was 
negative. EMB-histology findings included an eosinophil-rich inflammatory infiltrate, leukocytoclasia, 
fibrinoid necrosis and myocardial necrosis. Despite intensive care (mechanical ventilation, inotropes, 
left ventricular assist device) and corticosteroids, several ventricular arrhythmia episodes (tachycardia 
and fibrillation) occurred. OHT was performed successfully on 30 March 2003, in San Matteo 
Hospital, Pavia, Italy. Examination of the explanted heart found the same histopathologic pattern as 
pre-transplantation EMB. The patient’s health improved, and she was discharged on prednisone, 
cyclosporine (600 mg/day), statin and a calcium-channel blocker. 
 She had no clinical or biologic sign of disease activity at her last consultation in September 
2008: echocardiography, routine coronarography and EMB were normal. In December 2008, a few 
days after influenza vaccination, she developed fever, arthralgias and myalgias, and died suddenly. No 
autopsy was performed. An infectious disease (particularly viral myocarditis) or acute arrhythmia due 
to EGPA relapse and/or graft rejection are plausible explanations of the patient’s death. Notably, the 
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patient was at high immunologic risk. Indeed, she had had several pregnancies, had benefited from a 
left ventricular heart assist device before transplantation and had received 12 units of red blood cells 
during the procedure. Finally, no HLA typing and no anti-HLA antibody screening had been 
performed. 
 
Case 8 
 
Part of this case was previously reported.
2
 Briefly, a 38-year-old man, with a 1-year history of late-
onset asthma treated with inhaled steroids, was hospitalized in October 2004 for dyspnea and chest 
discomfort. Physical examination found bilateral wheezing and symmetric swelling of both legs 
consistent with edema. Laboratory findings were elevated C-reactive protein (69.2 mg/liter), troponin I 
(4.06 g/liter) and blood eosinophilia (8.5 cells/ml). ECG showed sinus tachycardia, delayed R 
progression on V1–V4, ST-elevation on V1–V2 and ST depression on V6. LVEF was estimated at 
30% by echocardiography, which also revealed a 300-ml pericardial effusion. Chest X-ray showed 
bilateral lung infiltrates; coronary angiogram was normal. Although immunofluorescence testing for 
ANCA yielded a cytoplasmic-labeling pattern, enzyme-linked immunosorbent assay was negative for 
antibodies to proteinase-3 or myeloperoxidase. EMB contained an eosinophil-rich infiltrate and EGPA 
was diagnosed.  
Oral immunosuppressants (prednisone 40 mg/day and methotrexate 15 mg twice weekly) were 
started. During prednisone tapering, the patient’s condition deteriorated with CHF, asthma 
exacerbation and further LVEF decline, echocardiographically evaluated at 22%. Cyclophosphamide 
pulses were started to replace methotrexate. Despite simultaneous adjusted heart-failure medication, 
LVEF declined to 15% in February 2005, when he was placed on the “urgent” heart-transplantation 
waiting list. OHT was performed in October 2005 in the University of Heidelberg Hospital, Germany. 
Nine months post-OHT, under corticosteroids, tacrolimus (3 mg/day) and mycophenolate mofetil (1 g 
bid), routine EMB revealed acute grade-1R CMR that did not require immunosuppressant 
intensification. To date, that has been the only graft-rejection episode, and no EGPA relapse has 
occurred. However, in spring 2012, he developed venous occlusion of the retina and macular edema 
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requiring a slow-release intravitreal dexamethasone implant. Seven years post-OHT, the patient is well 
and has no activity limitation.  
 
Case 9 
 
This patient’s medical history has already been published.3,4 Briefly, a previously healthy 22-year-old 
man was diagnosed with pulmonary eosinophilia in July 1986 [breathlessness, wheezing, bilateral 
interstitial lung opacities and pronounced eosinophilia (7.7 cells/ml). Despite corticosteroids, he 
developed CHF 1 year later due to severe dilated cardiomyopathy (LVEF estimated at 15%) and 
recurrent eosinophilia (3 eosinophils/ml). EMB contained prominent foci of young fibroblasts with 
necrotic and hypertrophied myocytes, and an infiltrate of lymphocytes, plasma cells, and eosinophils. 
No vasculitis was seen. Despite higher corticosteroid doses, he developed cardiogenic shock that 
required adrenaline, IABP and mechanical ventilation. OHT was performed in October 1987 in the 
Wythenshawe Hospital, Manchester, UK. Histologic examination of the explanted heart revealed foci 
of fibrinoid necrosis with giant cells in some intramyocardial vessels, mild eosinophilic infiltrate, 
subendocardial necrosis and arteritis in the right coronary artery. EGPA-related cardiomyopathy was 
diagnosed.  
 Two months after discharge, and despite immunosuppressants (i.e. corticosteroids and 
antithymoglobulins as induction therapy, and cyclosporine and azathioprine maintenance), the 
patient’s EGPA relapsed [cough, breathlessness and recurrent eosinophilia (2 eosinophils/ml], without 
any EMB sign of acute CMR, and corticosteroid dose was increased. Routine EMB showed no 
rejection or vasculitis until March 1991, when a moderate myocardial rejection episode was treated 
with a higher corticosteroid dose. In March 1992, he collapsed suddenly and died shortly thereafter, 
despite immediate cardiopulmonary resuscitation. Postmortem examination of the transplanted heart 
showed patchy areas of heart rejection and diffuse fibrinoid necrosis, chronic inflammation 
(containing lymphocytes, plasma cells and a few eosinophils) and proximal thrombotic occlusion of 
the right coronary artery, suggestive of an EGPA relapse. 
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 SUPPLEMENTAL TABLES 
 
Table S1 The 2004 International Society of Heart and Lung Transplantation Cardiac Biopsy Grading 
for Acute Cellular Rejection
aS
 
Grade Definition 
0R No rejection 
1R, mild Interstitial and/or perivascular infiltrate with up to 1 focus of myocyte 
damage 
2R, moderate Two or more foci of infiltrate with associated myocyte damage 
3R, severe Diffuse infiltrate with multifocal myocyte damage with or without edema, 
hemorrhage, or vasculitis 
a
Modified after Stewart et al. J Heart Lung Transplant 2005;24:1710-20.  
 
 
 
Table S2 The 2011 International Society of Heart and Lung Transplantation Working 
Formulation for Pathologic Diagnosis of  Antibody-Mediated Rejection (pAMR)
a
 
pAMR Description  
0 Histologic and immunopathologic studies are negative 
1 (H
+
) Positive histologic findings and negative immunopathologic findings 
1 (I
+
) Negative histologic findings and positive immunopathologic findings 
2 Histologic and immunopathologic findings are present 
3 Severe AMR with histopathologic findings of interstitial hemorrhage, capillary 
 fragmentation, mixed inflammatory infiltrates, endothelial cell pyknosis and/or 
 karyorrhexis and marked edema 
a
Modified after Berry et al. J Heart Lung Transplant 2011;24:1710-20. 
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ABBREVIATIONS 
AMR, antibody-mediated rejection; ANCA, antineutrophil cytoplasm antibodies; CAV, cardiac 
allograft vasculopathy; CHF, congestive heart failure; CMRI, cardiac magnetic resonance imaging; 
CMR, cell-mediated rejection; CMV, cytomegalovirus; CT, computed tomography; EGPA, 
eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome); EMB, endomyocardial 
biopsy; ENT = ear, nose and throat; IABP, intra-aortic balloon pump; HLA, human lymphocyte 
antigen; ICU, intensive care unit; LVEF, left ventricular ejection fraction; MF, myocardial fibrosis; 
OHT, orthotopic heart transplantation. 
 
CASE REPORTS 
 
Case 1  
 
A woman born in 1955 was diagnosed with eosinophilic granulomatosis with polyangiitis (Churg–
Strauss syndrome) (EGPA) in 1985 based on asthma, differential white-blood-cell–count eosinophilia, 
non-fixed pulmonary infiltrates, chronic paranasal sinus pain, skin biopsy showing perivascular 
inflammation with dense eosinophilic infiltrate and giant-cell granuloma in a context of arthralgias and 
pericarditis. Antineutrophil cytoplasm antibody (ANCA) serology was negative. Various treatments 
including azathioprine, methotrexate, cyclosporine and mycophenolate mofetil were administered until 
2009. During those years, she had many relapses, and successively developed polyneuritis, retro-
tympanic granuloma and eosinophilic gastroenteritis, while control of her asthma required continuous 
corticosteroids.  
In 2009, mitral regurgitation and severe dilated cardiomyopathy with left ventricular ejection 
fraction (LVEF) estimated at 33% were diagnosed. Coronary angiogram was normal. Despite 
cardioactive treatment, several episodes of acute congestive heart failure (CHF) and an episode of 
ventricular tachycardia treated with amiodarone occurred. Orthotopic heart transplantation (OHT) was 
performed in December 2009 in Niguarda Ca’ Granda Hospital in Milan, Italy. Histopathologic 
examination of the explanted heart found extensive myocardial fibrosis (MF), fibrinoid necrosis and 
ONLINE SUPPLEMENTARY MATERIAL
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an eosinophil-rich infiltrate (Figure 2). Outcome was favorable with immunosuppressive therapy 
(cyclosporine 175 mg bid, and azathioprine 75 mg/day enabling prednisone tapering), cardioactive 
therapy (atenolol 25 mg/day, ramipril 2.5 mg/day, aspirin 100 mg/day, and simavastatin 20 mg/day) 
and anti-cytomegalovirus (CMV) prophylaxis (valganciclovir 450 mg/day). 
 In February 2010, the patient developed atrial fibrillation, which was successfully treated with 
electrical cardioversion. Endomyocardial biopsy (EMB) showed a mixed acute cell (CMR)- and 
antibody-mediated rejections (AMR) (graded 1R and pAMR2, respectively; see Tables S1 and S2for 
explanations of acute CMR and AMR gradings) and eosinophilic granulocytes suggestive EGPA 
recurrence. Her health improved with intravenous immunoglobulins (25 g/day for 5 days) and pulse 
corticosteroids. Methotrexate (15 mg/week) was started and azathioprine was replaced by 
mycophenolate mofetil (550 mg bid). Since then, all EMBs have been normal.  
In July 2011, despite the absence of clinical or biologic signs of EGPA activity, the patient 
died suddenly. No autopsy was performed. 
 
Case 2  
 
In July 2007, a 52-year-old man, with a 3-year history of asthma and a CHF episode with normal 
coronary angiogram 3 years earlier, was diagnosed with EGPA: late asthma, non-fixed pulmonary 
infiltrates, sinusitis, eosinophilia (13.9 cells/ml), myocarditis, arthralgias and myalgias. ANCA 
serology was negative. Because of EGPA-related heart involvement, corticosteroids and 6 
cyclophosphamide pulses were prescribed.   
Two months later, he was admitted to the intensive care unit (ICU) with cardiac arrest. ECG 
showed asystole caused by severe hyperkalemia and renal failure resulting from decompensated 
corticosteroid-induced diabetes and angiotensin-converting-enzyme–inhibitor treatment. He recovered 
normal electric activity after cardiopulmonary resuscitation and adrenaline. His condition improved 
with insulin therapy and volume resuscitation. Azathioprine (150 mg/day) maintenance therapy was 
started but soon replaced by mycophenolate mofetil (1 g bid) due to toxidermia. 
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In January 2008, when a -blocker was introduced, his condition worsened. Cardiac magnetic 
resonance imaging (CMRI) (Figure 2) revealed severe dilated cardiomyopathy, mitral regurgitation, 
subepicardial delayed contrast enhancement in the septum and anterior wall, and T2-weighted 
hyperintensity in the same myocardial territory, consistent with edema. These findings were 
suggestive of active EGPA-related cardiomyopathy. He underwent OHT in March 2008 at Pitié–
Salpêtrière Hospital, Paris, France. Despite numerous post-operative complications (septic 
mediastinitis, septic shock due to Enterobacter aerogenes ventilator-associated pneumonia, acute 
CMV infection, severe polyneuromyopathy and chronic diarrhea due to Enterocytozoon bieneusi), he 
achieved full neurologic and functional recovery. However, he developed chronic kidney disease 
(glomerular filtration rate 40 ml/minute in 2012) as sequelae. Thirteen months post-OHT, EMB 
showed an acute grade-1R CMR (asymptomatic thus not requiring corticosteroids). Twenty-one 
months later, an asthma exacerbation required increasing the prednisone dose. 
Four years post-OHT, under a regimen of prednisone (10 mg/day), cyclosporine and 
mycophenolate mofetil, he has experienced no EGPA relapse or other graft rejection in routine EMBs.  
  
Case 3 
 
In 1999, a 36-year-old woman developed late-onset asthma followed, in June 2000, by severe CHF, 
intracavitary thrombosis, bilateral transudative pleural effusions, skin purpura, sinusitis and 
eosinophilia (1.9 cells/ml). EGPA was diagnosed in September 2000. ANCA serology was negative. 
Segmental pulmonary embolism and a right apical nodule were fortuitously diagnosed on her 
computed-tomography (CT) scan. EMB was uninformative. Despite corticosteroids, anticoagulant and 
cyclophosphamide pulses, she was transferred to the ICU under dobutamine, high-dose furosemide 
and interferon-α (3 MIU 3 times a week) added to her regimen. Echocardiography after dobutamine 
withdrawal estimated her LVEF at 15%. OHT was performed in October 2000 at Pitié–Salpêtrière 
Hospital.  
 Under immunosuppressants (tapering doses of prednisone, azathioprine 50 mg bid, 
cyclosporine 550 mg/day), her weekly EMB showed no sign of acute allograft rejection. In early 
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February 2001, she developed acute sinusitis and prednisone was increased to 60 mg/day by an ENT 
specialist. On 12 February 2001, she succumbed to sudden death, complaining of intense abdominal 
pain. Because no autopsy was performed, we can only speculate on the cause of her death. First, 
gastrointestinal perforation and subsequent fulminant peritonitis is a plausible explanation. Second, 
even though she had received cyclophosphamide pulses prior to OHT and was currently taking high 
corticosteroid doses, an EGPA relapse cannot be formally excluded. Lastly, graft rejection seems 
highly unlikely in this setting. 
 
Case 4  
 
In February 2003, a 35-year-old woman with a 15-year history of adult-onset asthma developed 
fulminant CHF secondary to myocarditis, requiring an intra-aortic balloon pump support (IABP). 
Initial laboratory analyses revealed marked eosinophilia (9.6 cells/ml). Her chest X-ray showed diffuse 
perihilar infiltrates suggestive of pulmonary edema and pleural effusions. A week later, a thoracic 
computed-tomography (CT) scan revealed a left infrahilar nodule. Echocardiography estimated LVEF 
at 25%. Bronchoscopy was uninformative. The patient initially received medical support and 
hydrocortisone. Work-up for an infectious or atopic etiology was negative. Transbronchial biopsy of 
the lung lesion revealed a fibrinopurulent exudate with Charcot–Laden crystals consistent with 
degenerating eosinophils.  Prednisone (70 mg/day) was prescribed and she was discharged. 
Thereafter, she was readmitted for a fainting episode attributed to hypotension and referred to 
another center where EGPA was diagnosed in late June 2003. Azathioprine (50 mg tid) was started, 
and corticosteroids were tapered and then stopped by November 2003, when a control thoracic CT 
scan showed resolution of the lung mass. In January 2004, an upper respiratory infection was treated 
with antibiotics and prednisone (30 mg/day). In March 2004, despite azathioprine, echocardiography 
found persistently low LVEF (20%) and a metabolic stress-test measured peak oxygen consumption at 
15.8 ml/kg/minute (50% of the predicted value for her age). OHT was performed 2 May 2004 at the 
Cleveland Clinic, Cleveland, OH, USA. On 10 May, she received corticosteroid pulses for grade-3R 
CMR. 
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Six months post-OHT, the patient developed shingles and another upper respiratory infection. 
Prednisone was withdrawn but restarted in August 2005, when she was taking cyclosporine (100 mg 
qid) and mycophenolate mofetil (125 mg qid) because of recurrent eosinophilia and asthma 
exacerbation. Long-term post-OHT medications include cyclosporine (100 mg bid), mycophenolate 
mofetil (1 g bid), prednisone (4 mg qid), lisinopril (5 mg bid), aciclovir (800 mg bid) and 
bronchodilatators as needed. Eight years post-OHT, no major EGPA relapse has occurred and no graft 
rejection has been seen on routine EMBs. 
 
Case 5 
 
In 2004, a 50-year-old patient, with a history of several bronchitis episodes during winters, systemic 
hypertension and dyslipidemia was diagnosed with EGPA: late-onset asthma, arthralgias, myalgias, 
skin purpura and subcutaneous nodules, mononeuritis multiplex and blood eosinophilia (9.79 cells/ml). 
ANCA serology was negative. Corticosteroids were started (initially 1 mg/kg/day for 3 weeks then 
doses were tapered). 
 Eighteen months later, in December 2005, while the patient’s symptoms regressed under 
corticosteroids, he was admitted to the ICU for CHF, chest pain and high troponin I levels (> 8 pg/ml). 
An 18-lead ECG showed no ST-segment abnormality but a grade-1 atrioventricular block. 
Echocardiography estimated LVEF at 18%, global hypokinesia, dilated left heart chambers, moderate 
mitral insufficiency and pericardial effusion. Coronary angiogram was normal. Histologic examination 
of an EMB revealed fibrinoid necrosis, an eosinophil-rich inflammatory infiltrate, extravascular 
granulomas and MF, thereby confirming the diagnosis of EGPA-related cardiomyopathy. Despite 
intensive therapy and positive inotropic support, his condition worsened. Emergency OHT was 
performed in March 2006 in the Sanatorio de la Trinidad Mitre Hospital, Buenos Aires, Argentina. 
The patient experienced several post-OHT complications. First, immunosuppressant side 
effects necessitated switching mycophenolate mofetil to azathioprine because of gastrointestinal 
disorders and cyclosporine to everolimus in early 2012 to counter moderate kidney failure, then 6 
years post-OHT he developed corticosteroid-associated aseptic necrosis of the hip requiring 
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arthroplasty. Second, 2 years post-OHT he developed disseminated miliary tuberculosis (involving 
lung, peritoneum and skin) that was treated with a 12-months of anti-tuberculosis drugs (including 2 
months of quadritherapy); 2 years after the end of treatment, he suffered a skin relapse and is currently 
taking isoniazid and rifampicin. Third, EGPA relapsed (skin purpura) 48 months post-OHT requiring 
prednisone intensification. Finally, he was recently diagnosed with severe grade-3 cardiac allograft 
vasculopathy (CAV) on a routine coronary angiogram. He is currently taking prednisone (40 mg/day), 
everolimus (1.5 mg/day) and azathioprine (150 mg/day). 
 
Case 6  
 
A 62-year-old man, with a history of late-onset asthma, anaphylactic shock after a bee sting, 
polypectomy for nasal polyposis, systemic hypertension and ventricular extrasystoles treated since 
2007 with carvedilol and flecainide, was admitted to the ICU in March 2008 with CHF and anterior 
ST-segment elevation. Transthoracic echocardiography estimated LVEF at 25% and visualized 
anterior hypokinesia, moderate mitral and tricuspid regurgitations, and an apical thrombus. The 
coronary angiogram was normal and chest CT angiography showed no evidence of pulmonary 
embolism. Blood analyses revealed hypereosinophilia (12.5 cells/ml). The patient’s condition finally 
improved with positive inotropic support and standard medical therapy. In June 2008, before 
discharge, an automatic cardioverter defibrillator was implanted because of frequent episodes of 
unsustained ventricular tachycardia.  
In August 2008, he was readmitted for CHF and malignant hypertension unresponsive to 
dopamine, nitroprusside and diuretics, and he was transferred to the ICU, where adrenaline, milrinone 
and IABP were started. Blood hypereosinophilia was confirmed. EMB contained an eosinophil-rich 
inflammatory infiltrate and EGPA was diagnosed. The patient was started on corticosteroids and 
underwent “extremely urgent” OHT on 16 September 2008 in Niguarda Ca’ Granda Hospital in Milan, 
Italy.  
The post-operative period was marked by acute CMV pneumonia, extended-spectrum -
lactamase Enterobacter cloacae sepsis and serum Aspergillus galactomannan antigen became positive. 
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He was successfully treated with ganciclovir, imipenem and voriconazole. In January 2009, EMB 
showed acute grade-1R CMR. Pulse corticosteroids were not administered but cyclosporine 
maintenance was switched to tacrolimus. 
Four years post-OHT, under prednisone (7.5 mg/day), tacrolimus (5 mg/day) and azathioprine 
(50 mg/day), EMBs scheduled biannually have shown no evidence of graft rejection. The patient is 
well but has mild functional limitations due to chronic renal dysfunction and osteoporosis.  
 
Case 7  
 
A 35-year-old woman was diagnosed with EGPA in 2003. Part of her medical history was previously 
reported.
1
 A few weeks postpartum, she developed fever, severe asthma, skin petechiae, polyarthralgia 
and CHF. Blood tests revealed 17.5 eosinophils/ml and a high troponin I level. ANCA serology was 
negative. EMB-histology findings included an eosinophil-rich inflammatory infiltrate, leukocytoclasia, 
fibrinoid necrosis and myocardial necrosis. Despite intensive care (mechanical ventilation, inotropes, 
left ventricular assist device) and corticosteroids, several ventricular arrhythmia episodes (tachycardia 
and fibrillation) occurred. OHT was performed successfully on 30 March 2003, in San Matteo 
Hospital, Pavia, Italy. Examination of the explanted heart found the same histopathologic pattern as 
pre-transplantation EMB. The patient’s health improved, and she was discharged on prednisone, 
cyclosporine (600 mg/day), statin and a calcium-channel blocker. 
 She had no clinical or biologic sign of disease activity at her last consultation in September 
2008: echocardiography, routine coronarography and EMB were normal. In December 2008, a few 
days after influenza vaccination, she developed fever, arthralgias and myalgias, and died suddenly. No 
autopsy was performed. An infectious disease (particularly viral myocarditis) or acute arrhythmia due 
to EGPA relapse and/or graft rejection are plausible explanations of the patient’s death. Notably, the 
patient was at high immunologic risk. Indeed, she had had several pregnancies, had benefited from a 
left ventricular heart assist device before transplantation and had received 12 units of red blood cells 
during the procedure. Finally, no HLA typing and no anti-HLA antibody screening had been 
performed. 
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Case 8 
 
Part of this case was previously reported.
2
 Briefly, a 38-year-old man, with a 1-year history of late-
onset asthma treated with inhaled steroids, was hospitalized in October 2004 for dyspnea and chest 
discomfort. Physical examination found bilateral wheezing and symmetric swelling of both legs 
consistent with edema. Laboratory findings were elevated C-reactive protein (69.2 mg/liter), troponin I 
(4.06 g/liter) and blood eosinophilia (8.5 cells/ml). ECG showed sinus tachycardia, delayed R 
progression on V1–V4, ST-elevation on V1–V2 and ST depression on V6. LVEF was estimated at 
30% by echocardiography, which also revealed a 300-ml pericardial effusion. Chest X-ray showed 
bilateral lung infiltrates; coronary angiogram was normal. Although immunofluorescence testing for 
ANCA yielded a cytoplasmic-labeling pattern, enzyme-linked immunosorbent assay was negative for 
antibodies to proteinase-3 or myeloperoxidase. EMB contained an eosinophil-rich infiltrate and EGPA 
was diagnosed.  
Oral immunosuppressants (prednisone 40 mg/day and methotrexate 15 mg twice weekly) were 
started. During prednisone tapering, the patient’s condition deteriorated with CHF, asthma 
exacerbation and further LVEF decline, echocardiographically evaluated at 22%. Cyclophosphamide 
pulses were started to replace methotrexate. Despite simultaneous adjusted heart-failure medication, 
LVEF declined to 15% in February 2005, when he was placed on the “urgent” heart-transplantation 
waiting list. OHT was performed in October 2005 in the University of Heidelberg Hospital, Germany. 
Nine months post-OHT, under corticosteroids, tacrolimus (3 mg/day) and mycophenolate mofetil (1 g 
bid), routine EMB revealed acute grade-1R CMR that did not require immunosuppressant 
intensification. To date, that has been the only graft-rejection episode, and no EGPA relapse has 
occurred. However, in spring 2012, he developed venous occlusion of the retina and macular edema 
requiring a slow-release intravitreal dexamethasone implant. Seven years post-OHT, the patient is well 
and has no activity limitation.  
 
Case 9 
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This patient’s medical history has already been published.3,4 Briefly, a previously healthy 22-year-old 
man was diagnosed with pulmonary eosinophilia in July 1986 [breathlessness, wheezing, bilateral 
interstitial lung opacities and pronounced eosinophilia (7.7 cells/ml). Despite corticosteroids, he 
developed CHF 1 year later due to severe dilated cardiomyopathy (LVEF estimated at 15%) and 
recurrent eosinophilia (3 eosinophils/ml). EMB contained prominent foci of young fibroblasts with 
necrotic and hypertrophied myocytes, and an infiltrate of lymphocytes, plasma cells, and eosinophils. 
No vasculitis was seen. Despite higher corticosteroid doses, he developed cardiogenic shock that 
required adrenaline, IABP and mechanical ventilation. OHT was performed in October 1987 in the 
Wythenshawe Hospital, Manchester, UK. Histologic examination of the explanted heart revealed foci 
of fibrinoid necrosis with giant cells in some intramyocardial vessels, mild eosinophilic infiltrate, 
subendocardial necrosis and arteritis in the right coronary artery. EGPA-related cardiomyopathy was 
diagnosed.  
 Two months after discharge, and despite immunosuppressants (i.e. corticosteroids and 
antithymoglobulins as induction therapy, and cyclosporine and azathioprine maintenance), the 
patient’s EGPA relapsed [cough, breathlessness and recurrent eosinophilia (2 eosinophils/ml], without 
any EMB sign of acute CMR, and corticosteroid dose was increased. Routine EMB showed no 
rejection or vasculitis until March 1991, when a moderate myocardial rejection episode was treated 
with a higher corticosteroid dose. In March 1992, he collapsed suddenly and died shortly thereafter, 
despite immediate cardiopulmonary resuscitation. Postmortem examination of the transplanted heart 
showed patchy areas of heart rejection and diffuse fibrinoid necrosis, chronic inflammation 
(containing lymphocytes, plasma cells and a few eosinophils) and proximal thrombotic occlusion of 
the right coronary artery, suggestive of an EGPA relapse. 
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Table 1     Patient Characteristics at Diagnosis of Eosinophilic Granulomatosis with Polyangiitis 
Patient 
Year of 
diagnosis 
Sex /age 
(year) 
 
Clinical manifestations 
Eosinophils  
(/ml) BVAS 
1 1985 F/26 Fever, sinusitis, asthma, lung infiltrates, myalgias, arthralgias, skin nodules, 
pericarditis 
3.2 23 
2 2007 M/54 Fever, sinusitis, asthma, lung nodule, lung infiltrates, myalgias, arthralgias, 
CHF 
13.9 31 
3 2000 F/36 Fever, sinusitis, asthma, lung nodule, pleural effusion, myalgias, arthralgias, 
skin purpura, deep vein thrombosis 
1.9 4 
4 2003 F/35 Sinusitis, asthma, lung nodule, lung infiltrates, pleural effusion, myalgias, 
arthralgias, hematuria, CHF 
9.6 42 
5 2004 M/50 Asthma, myalgias, arthralgias, mononeuritis multiplex, skin purpura, skin 
nodules 
9.8 27 
6 2008 M/62 Sinusitis, asthma, lung infiltrates, CHF 12.5 22 
Table 1
7 2003 F/35 Fever, sinusitis, asthma, arthralgias, skin purpura, CHF 17.5 38 
8 2004 M/38 Fever, sinusitis, asthma, lung infiltrates, pleural effusion, CHF 8.5 42 
9 1986 M/22 Fever, asthma, lung infiltrates 7.7 12 
ANCA, antineutrophil cytoplasm antibodies; BVAS, Birmingham Vasculitis Activity Score; CHF, congestive heart failure. 
 
Table 2     Patient Characteristics at Diagnosis of EGPA-Related Cardiomyopathy 
 
 
Patient 
EGPA-to- 
CMP interval 
(mo) 
 
CV risk  
factors 
 
Troponin I 
(μg/liter) 
NT  
pro-BNP 
(pg/ml) 
 
 
ECG 
 
LVEF 
(%) 
 
 
CMRI 
 
Coronary  
angiogram 
CMP-to- 
OHT interval 
(mo) 
1 288 High CH <0.04 3841 ST 33 ND Normal 7 
2 0 Age, smoker 10 1363 AR, ST 30 Anteroseptal STIR 
hyperintensity &  
Gd-DE 
40% stenosis 
of the anterior 
IVA 
9 
3 12 None 57 ND AR 19 ND Normal 15 
4 0 High CH 2.8 601 AR, ST 20 ND ND 15 
5 18 Age, HT 8.9 ND AVB 18 ND Normal 12 
6 0 Age, HT,  
high CH, FH 
ND 16,730 ST 25 ND Normal 5 
Table 2
7 0 Smoker 20 ND AR 25 ND ND 4 
8 0 None 4.1 32,397 AR, ST 30 Anterior Gd-DE Normal 12 
9 12 NR ND ND Low 
voltage 
15 ND ND 2 
AR, arrhythmia; AVB, atrioventricular block; CH, cholesterol; CMP, cardiomyopathy; CMRI, cardiac magnetic resonance imaging; CV, cardiovascular; 
ECG, electrocardiogram; EGPA, eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome); FH, family history of CV disease; Gd-DE, 
gadolinium delayed enhancement; HT, hypertension; IVA, interventricular artery; LVEF, left ventricular ejection fraction; mo, month; ND, not done; NR, 
not reported; NT pro-BNP, N-terminal prohormone of brain natriuretic peptide; STIR, T2-weighted short axis inversion recovery; ST, ST-segment 
abnormality. 
 
Table 4     Post-Transplantation Outcomes 
      EGPA Graft     Follow-  
 OHT Treatment  relapse rejection
a
   Other  up 
Patient year Induction Maintenance Cardioactive Status (mo) (mo) CAV Infection complications VDI (mo) 
1 2009 ATG CS, CyA, 
AZA, MMF, 
MTX, IVIg 
BB, ACEI, 
statins, AP,  
D 
Died Yes (5) CMR 1R, 
pAMR2  
(5) 
No CMV 
replication 
Yes 1 11 
2 2008 ATG CT, CyA, 
AZA, MMF 
ACEI, statins, 
AP,  
D 
Alive Asthma 
flare (34) 
CMR 1R  
(13) 
No Septic 
mediastinitis, 
VAP, 
Microsporidia, 
CMV 
replication 
Yes 9 55 
3 2000 OKT3 CS, CyA, ACEI, statins, Died Sinusitis No No None None 2 3 
Table 4
AZA AP (3) 
4 2004 None CS, CyA, 
MMF 
BB, ACEI, 
statins, D 
Alive Asthma 
flare (15) 
CMR 3R  
(1) 
No Herpes zoster None 0 102 
5 2006 Anti-IL-2R CS, CyA, 
PSI, MMF, 
AZA 
ACEI, statins, 
AP 
Alive Yes (48) No Yes Disseminated 
tuberculosis 
Yes 7 80 
6 2008 ATG CS, CyA, 
TAC, AZA 
ACEI, AP Alive No CMR 1R 
 (4) 
No CMV and 
Aspergillus sp. 
Yes 4 47 
7 2003 ATG CS, CyA, 
AZA 
ACEI, statins Died No No No None Yes 0 60 
8 2005 None CS, TAC, 
MMF 
ACEI, statins Alive No CMR 1R  
(72) 
No None Yes 3 85 
9 1987 ATG CS, CyA, NR Died Yes (2) CMR 2R  Yes CMV None ND 53 
AZA (41) replication 
ACEI, angiotensin-converting–enzyme inhibitor or sartan; AMR, antibody-mediated rejection; anti-IL-2R, anti-interleukin-2–receptor antibodies; AP, anti-platelet; 
ATG, antithymoglobulin; AZA, azathioprine; BB, β-blocker, CAV, cardiac allograft vasculopathy; CH, cholesterol; CMR, cell-mediated rejection; CMV, 
cytomegalovirus; CS, corticosteroids; CyA, cyclosporine, D, diuretics; DM, diabetes mellitus; EGPA, eosinophilic granulomatosis with polyangiitis (Churg–Strauss 
syndrome); HT, hypertension; IVIg, intravenous immunoglobulins; MMF, mycophenolate mofetil; MTX, methotrexate; NR, not reported; OHT, orthotopic heart 
transplantation; OKT3, muromonab-CD3; PSI, proliferation signal inhibitor; TAC, tacrolimus; VAP, ventilator-associated pneumonia; VDI, Vasculitis Damage 
Index. 
a
See Online Supplemental Material for explanations of grading of biopsies showing acute CMR and AMR working formulation. 
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Table 3     Histologic Findings 
Patient Pre-graft EMB Explanted heart Post-graft EMB 
1 ND Fibrinoid necrosis, eosinophil-rich inflammatory infiltrate, 
giant cells, myocardial fibrosis 
CMR (1R), AMR (pAMR2), 
eosinophil-rich inflammatory 
infiltrate  
2 ND Atheroma, myocardial fibrosis, left ventricular endomyocardial 
fibrosis 
CMR (1R) 
3 Normal Myocardial fibrosis, myocardial necrosis Normal 
4 NR Small-vessel mixed neutrophilic and lymphocytic infiltrates CMR (3R) 
5 Fibrinoid necrosis, eosinophil-rich inflammatory 
infiltrate, extravascular granulomas, myocardial 
fibrosis, myocardial necrosis 
Atheroma, fibrinoid necrosis, eosinophil-rich inflammatory 
infiltrate, myocardial fibrosis, myocardial necrosis 
Myocardial necrosis 
6 Eosinophil-rich inflammatory infiltrate Extravascular granulomas, myocardial fibrosis CMR (1R) 
7 Fibrinoid necrosis, leukocytoclasia, eosinophil- Fibrinoid necrosis, perivascular eosinophil-rich inflammatory Normal 
Table 3
rich inflammatory infiltrate, myocardial necrosis infiltrate, myocardial necrosis, medium-sized coronary branch 
thromboses 
8 Eosinophil-rich inflammatory infiltrate,  
myocardial necrosis 
Leukocytoclasia, myocardial fibrosis CMR (1R) 
9 Eosinophil-rich inflammatory infiltrate,  
myocardial necrosis 
Fibrinoid necrosis, eosinophil-rich inflammatory infiltrate, 
myocardial necrosis, giant cells, right coronary artery arteritis 
CMR (2R) 
AMR, antibody-mediated rejection; pAMR, pathologic AMR; CMR, cell-mediated rejection; EMB, endomyocardial biopsy; ND, not done; NR, not 
reported. 
 
 
